Thermo Fisher Scientific (NYSE:TMO) Price Target Raised to $635.00

Thermo Fisher Scientific (NYSE:TMO) had its price target raised by Wells Fargo & Company from $565.00 to $635.00 in a research note issued to investors on Thursday,Benzinga reports. The firm currently has an overweight rating on the medical research company’s stock.

Other equities research analysts also recently issued research reports about the company. HSBC restated a “hold” rating and issued a $510.00 target price on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Scotiabank raised shares of Thermo Fisher Scientific from a “sector perform” rating to a “sector outperform” rating and set a $590.00 price target on the stock in a research note on Friday, July 11th. Redburn Partners set a $580.00 price objective on shares of Thermo Fisher Scientific in a research report on Wednesday, October 8th. Weiss Ratings reissued a “hold (c)” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, October 14th. Finally, Evercore ISI upped their price target on Thermo Fisher Scientific from $525.00 to $590.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 7th. Nineteen equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $595.75.

Thermo Fisher Scientific Trading Up 0.2%

Shares of TMO stock opened at $573.07 on Thursday. Thermo Fisher Scientific has a twelve month low of $385.46 and a twelve month high of $610.97. The stock has a market cap of $216.40 billion, a price-to-earnings ratio of 33.11, a PEG ratio of 3.24 and a beta of 0.77. The company’s 50-day moving average price is $504.04 and its 200-day moving average price is $453.55. The company has a current ratio of 1.50, a quick ratio of 1.50 and a debt-to-equity ratio of 0.62.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, beating the consensus estimate of $5.50 by $0.29. The company had revenue of $11.12 billion for the quarter, compared to analyst estimates of $10.90 billion. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. Thermo Fisher Scientific’s revenue was up 4.9% on a year-over-year basis. During the same period in the previous year, the business posted $5.28 EPS. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. As a group, equities analysts predict that Thermo Fisher Scientific will post 23.28 earnings per share for the current year.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 400 shares of the business’s stock in a transaction dated Friday, September 5th. The stock was sold at an average price of $500.50, for a total transaction of $200,200.00. Following the completion of the transaction, the chief executive officer directly owned 113,762 shares of the company’s stock, valued at approximately $56,937,881. The trade was a 0.35% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CAO Joseph R. Holmes sold 385 shares of the firm’s stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $492.63, for a total transaction of $189,662.55. Following the completion of the sale, the chief accounting officer directly owned 2,319 shares in the company, valued at approximately $1,142,408.97. This trade represents a 14.24% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 29,666 shares of company stock worth $13,990,971. Insiders own 0.33% of the company’s stock.

Institutional Investors Weigh In On Thermo Fisher Scientific

Several institutional investors have recently modified their holdings of the company. CBIZ Investment Advisory Services LLC boosted its position in shares of Thermo Fisher Scientific by 137.5% during the 1st quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock worth $28,000 after acquiring an additional 33 shares in the last quarter. Highline Wealth Partners LLC lifted its stake in Thermo Fisher Scientific by 126.9% during the third quarter. Highline Wealth Partners LLC now owns 59 shares of the medical research company’s stock worth $29,000 after purchasing an additional 33 shares during the last quarter. Anderson Financial Strategies LLC purchased a new position in Thermo Fisher Scientific in the first quarter valued at approximately $30,000. Keystone Global Partners LLC acquired a new stake in Thermo Fisher Scientific during the first quarter worth approximately $31,000. Finally, IMA Advisory Services Inc. acquired a new position in shares of Thermo Fisher Scientific in the 1st quarter valued at $35,000. 89.23% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.